California-based biotech Avanir Pharmaceuticals today announced funding from The Michael J. Fox Foundation for a clinical study of a drug designed to treat dyskinesia in people with Parkinson’s.

The study will test the safety and efficacy of their drug called AVP-923 (dextromethorphan hydrobromide and quinidine sulfate), and will be conducted at three centers across the United States and Canada. According to Avanir, the trial will be a proof-of-concept study designed to compare their drug with a placebo treatment.

AVP-923 is also currently in development to treat multiple sclerosis.